CTIS2023-506029-12-00招募中1 期
Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerability, and the Consistency of Effect of Atogepant for the Acute Treatment of Migraine (ECLIPSE) - M24-305
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 1,300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Subjects must voluntarily sign and date an informed consent, approved by an IEC/IRB, prior to the initiation of any screening or study-specific procedures., Female subjects (or individuals) of childbearing potential must practice at least 1 protocol-specified method of birth control, from 30 days prior to Visit 2/Randomization until 30 days after the last dose of study drug. Female subjects of nonchildbearing potential do not need to use birth control., Male subjects who are sexually active with female partner(s) of childbearing potential must agree to practice the protocol-specified contraception, and not plan to father a child or donate sperm, from Visit 2/Randomization until 30 days after the last dose of study drug., Has used prescription or nonprescription medication for the acute treatment of migraine in the past., Oral migraine medications used for prophylaxis on-label or off-label (e.g., topiramate, amitriptyline, beta blockers, flunarizine, venlafaxine, etc.) and injectable onabotulinum toxin A are permitted provided that the treatment is stable for at least 3 months prior to Visit 2/Randomization and continues without change in dose throughout the study., Subjects enrolling in the Triptan-Unsuitable substudy (applicable only after completion of enrollment in the main study) must meet all the inclusion criteria listed for the main study and must not meet any of the exclusion criteria listed for the main study. In addition, subjects must meet the following inclusion criterion: Subject must be triptan-unsuitable defined as meeting 1 of the 2 following criteria: -has a contraindication to triptans based upon local label and investigator judgment, irrespective of prior triptan use OR meets the following triptan failure definition for =2 different triptans: Currently uses a triptan or has used a triptan in the past and has not achieved pain relief (defined as the reduction of a moderate/severe migraine headache to a mild headache or no headache) at 2 hours postdose in =2 out of 4 attacks based upon subject interview and investigator judgment OR -Used a triptan in the past but no longer uses a triptan due to AEs based upon subject interview and investigator judgment., Ability and willingness to read, understand, and complete study questionnaires and eDiary., Aged 18 to 75 years, inclusive, at Visit 1/Screening (subjects must also meet the legal age of majority per local law)., History of migraine (with or without aura) according to the ICHD-3 for =12 months prior to Visit 1/Screening., Migraine onset before the age of 50., History of migraines lasting between 4 to 72 hours when untreated or treated unsuccessfully and migraine episodes separated by at least 48 hours of headache pain freedom., History of 2 to 8 migraine attacks per month with moderate to severe headache pain in each of the 3 months prior to Visit 1/Screening per investigator judgment., Female subjects who are not pregnant or breastfeeding, and are not planning to become pregnant or donate eggs during the study and for approximately 30 days after the last dose of study drug., Female subjects (or individuals) of childbearing potential must have a negative serum pregnancy test at Visit 1/Screening and a negative urine pregnancy test at Visit 2/Randomization. Subjects with a borderline serum pregnancy test at Visit 1/Screening must have absence of clinical suspicion of pregnancy or other pathological causes of borderline results and a serum pregnancy test =3 days later
排除标准
- •Subject has difficulty in distinguishing migraine headache from tension-type or other headaches per the investigator's judgment., Positive result on the urine drug screen at Visit 1/Screening unless explained by disclosed concomitant medication use (e.g., opioids prescribed for migraine pain, use of benzodiazepines for insomnia)., Positive result on the hepatitis B surface antigen or the anti-hepatitis C antibody testing at Visit 1/Screening., Presence of other confounding pain syndromes, confounding psychiatric conditions, dementia, epilepsy and other significant neurological disorders other than migraine per investigator judgment., Presence of chronic, nonheadache pain condition requiring daily pain medication., Clinically significant cardiovascular, cerebrovascular, hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, psychiatric, or neurologic disease. -If there is a history of such disease but the condition has been stable for more than 6 months prior to Visit 1/Screening and is judged by the investigator as not likely to interfere with the subject's participation in the study, the subject may be included. -Subjects on dialysis for renal failure are not allowed to participate in the study., Significant risk of self-harm, based on clinical interview or responses on the C-SSRS, or harm to others per the opinion of the investigator; subjects must be excluded if they report suicidal ideation with intent, with or without a plan (i.e., Type 4 or 5 on the C-SSRS) in the past 6 months or report suicidal behavior in the last 6 months prior to Visit 1/Screening or Visit 2/Randomization., History of malignancy in the 5 years prior to Visit 1/Screening, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer., History of any prior gastrointestinal conditions (e.g., diarrhea syndromes, inflammatory bowel disease) that may affect the absorption or metabolism of study drug. -Subjects with prior gastric bariatric interventions (e.g., Lap Band) which have been reversed may participate., History of acute hepatitis within 6 months of Visit 1/Screening or any history of chronic liver disease (including nonalcoholic fatty liver disease, viral chronic hepatitis, and cirrhosis)., History of hypersensitivity or clinically significant adverse reaction to a CGRP receptor antagonist., History of an average of 15 or more headache days per month in the 6 months prior to Visit 1/Screening per the investigator's judgment, or a current diagnosis of chronic migraine as defined by ICHD-3. (Note: subjects with a diagnosis of chronic migraine who, in the opinion of the investigator, have fewer than 15 headache days per month due to concomitant prophylactic treatment are allowed to participate in the study)., Subject is an employee or immediate family member (parents, spouses, siblings, or children) of one of the investigators, study staff, or AbbVie., Subject has condition or situation, which the investigator feels will compromise the safety of the subject or the quality of the data and renders the subject an unsuitable candidate for the study., Subject has taken medication for acute treatment of headache (including acetaminophen, NSAIDs, triptans, ditans, ergotamine, opioids, gepants, or combination analgesics) 10 or more days per month in any of the 3 months prior to Visit 2/Randomization., Subject has taken strong CYP3A4 inhibitors, including but not limited to systemic (oral/IV) itraconazole, ketoconazole,
研究者
相似试验
撤回
2 期
Randomized, Double-Blind, Placebo-Controlled, Multicenter, Exploratory Phase II Study to Compare Three Dose Regimens of GLPG0259 vs Placebo, in Combination with Methotrexate, Administered for 12 Weeks to Subjects with Active Rheumatoid Arthritis and an Inadequate Response to Methotrexatechronische gewrichtsaandoeninginflammation of the joints10003816NL-OMON34069Galapagos NV6
进行中（未招募）
不适用
Randomized, Double-Blind, Placebo-Controlled, Multicenter, Exploratory Phase II Study to Compare Three Dose Regimens of GLPG0259 vs Placebo, in Combination with Methotrexate, Administered for 12 Weeks to Subjects with Active Rheumatoid Arthritis and an Inadequate Response to MethotrexatePatients with active rheumatoid arthritis and an inadequate response to MethotrexateMedDRA version: 13.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2009-015898-12-NLGalápagos NV200
进行中（未招募）
不适用
Randomized, Double-Blind, Placebo-Controlled, Multicenter, Exploratory Phase II Study to Compare Three Dose Regimens of GLPG0259 vs Placebo, in Combination with Methotrexate, Administered for 12 Weeks to Subjects with Active Rheumatoid Arthritis and an Inadequate Response to MethotrexateEUCTR2009-015898-12-BEGalápagos NV200
进行中（未招募）
1 期
A study to evaluate ExPEC9V vaccine for the prevention of Invasive E. coli Disease in adults aged 60 years and older with a history of urinary tract infection in the past two years.Invasive Extraintestinal Pathogenic Escherichia coli DiseaseMedDRA version: 21.1Level: PTClassification code 10052238Term: Escherichia urinary tract infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: HLTClassification code 10015295Term: Escherichia infectionsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-005273-27-ESJanssen Vaccines & Prevention B.V18,556
进行中（未招募）
1 期
A study to evaluate ExPEC9V vaccine for the prevention of Invasive E. coli Disease in adults aged 60 years and older with a history of urinary tract infection in the past two years.Invasive Extraintestinal Pathogenic Escherichia coli DiseaseMedDRA version: 21.1Level: PTClassification code 10052238Term: Escherichia urinary tract infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: HLTClassification code 10015295Term: Escherichia infectionsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-005273-27-DKJanssen Vaccines & Prevention B.V18,556